PLICO Biotech is a pre-clinical stage biotech company focused on  treating Alzheimer and related disorders. Recent failures in clinical
trials by some of the biggest pharmaceutical companies (for instance, between 2000 and 2012, 244 compounds were tested in 413 clinical trials
for the treatment of neurodegeneration, only one was approved for use, showing a failure rate of 99.6 percent) have highlighted the need to
rethink the pharmacological strategies against neurodegenerative disorders and aggregopathies in general. The scientific community has
realized that we do not know enough about the molecular mechanisms that drive these conditions, and more basic research is required to find a
cure for them. At Plico Biotech we utilize a specific molecule, targeting a regulatory pathway that can rescue the toxicity of various proteins involved in neurodegenerative disease. We have identified a protein pharmaceutical called PLB002 that works via a unique pathway to prevent the toxicity of such proteins inside neurons.